Cibus (CBUS) AI Stock Analysis

• Market Cap: $111.06M
• Dividend Yield: N/A
• Average Volume (3M): 147.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.66
• Revenue Growth: 104.78%
• EPS Growth: 40.41%
• Country: US
• Employees: 157
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -1.34
• Shares Outstanding: 32,672,180
• 10 Day Avg. Volume: 172,850
• 30 Day Avg. Volume: 147,198
• PEG Ratio: 0.16
• Price to Book (P/B): 1.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.01
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 5.87
• Enterprise Value/Gross Profit: 31.38
• Enterprise Value/Ebitda: -0.07
• 1Y Price Target: $22.00
• Price Target Upside: 581.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $3.00 ▼(-7.12%Downside)

Cibus's overall score reflects significant financial challenges, with persistent net losses and negative cash flows weighing heavily. Despite some positive momentum in technical indicators and regulatory achievements, the valuation concerns and cash burn issues remain significant risks.

Positive Factors

International Market Expansion

The recent endorsement by EU member states on the regulation of plants obtained by New Genomic Techniques could eventually translate into an expanded market opportunity for Cibus in Europe.

Regulatory Approval

The USDA-APHIS determined that the plants developed using Cibus’ RTDS gene editing technology do not fall under the definition of a 'regulated article' and therefore won’t be subject to regulations.

Revenue Growth

Cibus' revenues increased by 135% year-over-year, mainly through collaboration agreements and sales related to developing a palm oil alternative.

Negative Factors

Financial Loss

The company produced a net loss of ~$47M, widening over 300% y/y, primarily due to a significant goodwill impairment charge.

Leadership Change

Cibus' CEO, Rory Riggs, will be stepping down from his leadership position, marking a significant leadership change.

Cibus Business Overview & Revenue Model

Company Description

Cibus (CBUS) is a leading agricultural biotechnology company focused on developing and commercializing gene-edited crops. The company operates primarily in the agriculture and biotechnology sectors, offering innovative solutions that enhance crop yields, improve resistance to diseases and pests, and increase environmental sustainability. Cibus leverages advanced gene-editing technologies to create high-performance crop varieties that meet the evolving needs of farmers and the global food supply chain.

How the Company Makes Money

Cibus makes money through the development and commercialization of gene-edited crops. The company generates revenue by licensing its proprietary gene-editing technologies and crop varieties to agricultural producers and seed companies. Additionally, Cibus may enter into strategic partnerships and collaborations with industry stakeholders to co-develop and market new crop varieties. These partnerships can result in milestone payments, royalties, and co-marketing agreements that contribute to the company's earnings. Cibus's business model is heavily reliant on the successful adoption of its technologies by the agricultural sector and the ongoing demand for improved crop varieties.

Cibus Financial Statement Overview

Summary

Cibus is experiencing financial distress with persistent net losses, high debt levels, and negative cash flows. Despite revenue growth, the financial health is hampered by substantial net losses and negative profitability margins.

Income Statement

Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.

Balance Sheet

The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.

Cash Flow

Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.75M	4.26M	1.82M	157.00K	25.99M	23.85M
	Gross Profit
3.02M	4.26M	1.42M	-1.38M	-2.57M	-11.28M
	EBIT
-281.51M	-258.40M	-318.88M	-22.37M	-29.33M	-43.83M
	EBITDA
-264.21M	-241.63M	-314.58M	-15.21M	-25.43M	-41.53M
	Net Income Common Stockholders
-274.84M	-251.39M	-267.63M	-16.89M	-29.20M	-44.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
32.70M	14.43M	32.70M	3.43M	13.82M	29.00M
	Total Assets
544.41M	350.07M	544.41M	22.42M	37.19M	63.33M
	Total Debt
24.62M	36.29M	24.62M	13.54M	17.88M	19.76M
	Net Debt
-8.08M	21.85M	-8.08M	10.12M	4.05M	2.46M
	Total Liabilities
206.12M	252.24M	206.12M	15.19M	23.06M	26.45M
	Stockholders Equity
293.47M	92.16M	293.47M	7.23M	14.13M	36.88M
Cash Flow		Free Cash Flow
-82.04M	-58.85M	-50.53M	-20.88M	-19.31M	-45.46M
	Operating Cash Flow
-80.78M	-58.04M	-46.21M	-19.36M	-18.81M	-43.67M
	Investing Cash Flow
-1.26M	-808.00K	55.06M	-1.52M	11.20M	-13.48M
	Financing Cash Flow
56.35M	40.60M	20.32M	9.99M	3.74M	15.41M

Cibus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.23
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Positive. The current price of 3.23 is above the 20-day moving average (MA) of 2.61, above the 50-day MA of 2.17, and below the 200-day MA of 3.37, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 64.05 is Neutral, neither overbought nor oversold. The STOCH value of 88.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBUS.

Cibus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGX	54 Neutral	$63.55M	―	-31.93%	―	-4.22%	18.67%
Sector *	53 Neutral	$5.22B	3.32	-45.04%	2.83%	16.81%	-0.27%
CBUS	51 Neutral	$111.06M	―	-157.73%	―	104.78%	40.41%
KRON	46 Neutral	$41.15M	―	-59.49%	―	21.15%	46.44%
GANX	46 Neutral	$53.00M	―	-290.21%	―	-100.00%	44.28%
INZY	37 Underperform	$256.31M	―	-141.69%	―	―	-17.06%
AVTX	37 Underperform	$43.31M	―	678.24%	―	-69.59%	―

Cibus Corporate Events

Cibus Stockholders Approve 2025 Employee Stock Plan

On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.

Cibus Approves Key Measures at Annual Meeting

On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.

The most recent analyst rating on (CBUS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Cibus stock, see the CBUS Stock Forecast page.